Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.

The Cyfra 21.1 assay is a newly developed test which measures in serum a fragment of cytokeratin 19. We evaluated this marker in 212 patients with non-small-cell lung cancer (NSCLC), predominantly stage 3a-b and 4, and compared it with three other markers: carcinoembryonic antigen (CEA), squamous ce...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Gaast, A., Schoenmakers, C. H., Kok, T. C., Blijenberg, B. G., Cornillie, F., Splinter, T. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968860/
https://www.ncbi.nlm.nih.gov/pubmed/7510117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968860/
https://www.ncbi.nlm.nih.gov/pubmed/7510117

Ejemplares similares